Floc'h, Nicolas <br/><br/>
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.  [electronic resource] 

 -  Molecular cancer therapeutics  05 2018 
 - 885-896 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-17-0758  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acrylamides<br/>Aniline Compounds<br/>Animals<br/>COS Cells<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>Chlorocebus aethiops<br/>ErbB Receptors--antagonists & inhibitors<br/>Exons--genetics<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Mice, SCID<br/>Mutation<br/>Piperazines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Xenograft Model Antitumor Assays--methods